Linda S. Ahn

Linda S. Ahn

Auto-generated profile, based on publicly available information

Linda S. Ahn

Memorial Sloan Kettering Cancer Center, New York, NY 10065, USA

Research Focus & Metrics

Academic Career Length

4Years (2023-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
2 February 2023 in Clinical Cancer Research
Verified
Journal Article
Closed access
PDF file
AEArielle Elkrief
Arielle Elkrief
AMAlex Makhnin
Alex Makhnin
KMKhadeja A. Moses
Khadeja A. Moses
LALinda S. Ahn
Linda S. Ahn
IPIsabel R. Preeshagul
Isabel R. Preeshagul
HYHelena A. Yu
Helena A. Yu
Purpose: Primary and acquired resistance to osimertinib remain significant challenges for patients with EGFR-mutant lung cancers. Acquired EGFR alterations such as EGFR T790M or C797S mediate resistance to EGFR tyrosine kinase inhibitors (TKI) and combination therapy with dual EGFR TKIs may prevent or reverse on-target resistance. Patients and Methods: We conducted two prospective, phase I/II trials assessing combination osimertinib and dacomitinib to address on-target resistance in the primary and acquired resistance settings. In the initial therapy study, patients received dacomitinib and osimertinib in combination as initial therapy. In the acquired resistance trial, dacomitinib with or without osimertinib was administered to patients with EGFR-mutant lung cancers with disease progression on osimertinib alone and evidence of an acquired EGFR second-site mutation. Results: Cutaneous toxicities occurred in 93% (any grade) of patients and diarrhea in 72% (any grade) with the combination. As initial therapy, the overall response to the combination was 73% [95% confidence interval (CI), 50%–88%]. No acquired secondary alterations in EGFR were observed in any patients at progression. In the acquired resistance setting, the overall response was 14% (95% CI, 1%–58%). Conclusions: We observed no acquired secondary EGFR alterations with dual inhibition of EGFR as up-front treatment, but this regimen was associated with greater toxicity. The combination was not effective in reversing acquired resistance after development of a second-site acquired EGFR alteration. Our study highlights the need to develop better strategies to address on-target resistance in patients with EGFR-mutant lung cancers.

1 April 2023
Verified
Other
Open access
AEArielle Elkrief
Arielle Elkrief
AMAlex Makhnin
Alex Makhnin
KMKhadeja A. Moses
Khadeja A. Moses
LALinda S. Ahn
Linda S. Ahn
IPIsabel R. Preeshagul
Isabel R. Preeshagul
HYHelena A. Yu
Helena A. Yu
Supplemental Figure 2. Dose modifications of Dacomitinib +/- Osimertinib (acquired resistance study).

1 April 2023
Verified
Other
Open access
AEArielle Elkrief
Arielle Elkrief
AMAlex Makhnin
Alex Makhnin
KMKhadeja A. Moses
Khadeja A. Moses
LALinda S. Ahn
Linda S. Ahn
IPIsabel R. Preeshagul
Isabel R. Preeshagul
HYHelena A. Yu
Helena A. Yu
Supplemental Figure 2. Dose modifications of Dacomitinib +/- Osimertinib (acquired resistance study).

1 April 2023
Verified
Other
Open access
AEArielle Elkrief
Arielle Elkrief
AMAlex Makhnin
Alex Makhnin
KMKhadeja A. Moses
Khadeja A. Moses
LALinda S. Ahn
Linda S. Ahn
IPIsabel R. Preeshagul
Isabel R. Preeshagul
HYHelena A. Yu
Helena A. Yu
Supplemental Figure 3. A. Median progression-free survival and B. Overall survival for patients enrolled in the initial therapy study

14 April 2023
Verified
Other
Open access
AEArielle Elkrief
Arielle Elkrief
AMAlex Makhnin
Alex Makhnin
KMKhadeja A. Moses
Khadeja A. Moses
LALinda S. Ahn
Linda S. Ahn
IPIsabel R. Preeshagul
Isabel R. Preeshagul
HYHelena A. Yu
Helena A. Yu
Purpose:Primary and acquired resistance to osimertinib remain significant challenges for patients with EGFR-mutant lung cancers. Acquired EGFR alterations such as EGFR T790M or C797S mediate resistance to EGFR tyrosine kinase inhibitors (TKI) and combination therapy with dual EGFR TKIs may prevent or reverse on-target resistance.Patients and Methods:We conducted two prospective, phase I/II trials assessing combination osimertinib and dacomitinib to address on-target resistance in the primary and acquired resistance settings. In the initial therapy study, patients received dacomitinib and osimertinib in combination as initial therapy. In the acquired resistance trial, dacomitinib with or without osimertinib was administered to patients with EGFR-mutant lung cancers with disease progression on osimertinib alone and evidence of an acquired EGFR second-site mutation.Results:Cutaneous toxicities occurred in 93% (any grade) of patients and diarrhea in 72% (any grade) with the combination. As initial therapy, the overall response to the combination was 73% [95% confidence interval (CI), 50%–88%]. No acquired secondary alterations in EGFR were observed in any patients at progression. In the acquired resistance setting, the overall response was 14% (95% CI, 1%–58%).Conclusions:We observed no acquired secondary EGFR alterations with dual inhibition of EGFR as up-front treatment, but this regimen was associated with greater toxicity. The combination was not effective in reversing acquired resistance after development of a second-site acquired EGFR alteration. Our study highlights the need to develop better strategies to address on-target resistance in patients with EGFR-mutant lung cancers.

1 April 2023
Verified
Other
Open access
AEArielle Elkrief
Arielle Elkrief
AMAlex Makhnin
Alex Makhnin
KMKhadeja A. Moses
Khadeja A. Moses
LALinda S. Ahn
Linda S. Ahn
IPIsabel R. Preeshagul
Isabel R. Preeshagul
HYHelena A. Yu
Helena A. Yu
Supplemental Figure 4. A. Median progression-free survival and B. Overall survival for patients enrolled in the acquired resistance study